End-of-day quote
Other stock markets
|
||
- USD | - |
05-23 | TFF Pharmaceuticals, Leidos to Advance Biodefense Countermeasures Into Preclinical Testing | MT |
05-14 | Leidos and Elroy Air to Demonstrate Autonomous Aerial Resupply Drone for U.S. Marine Corps | CI |
Sales 2024 * | 16.23B 22.15B | Sales 2025 * | 16.9B 23.08B | Capitalization | 20.44B 27.9B |
---|---|---|---|---|---|
Net income 2024 * | 1.05B 1.43B | Net income 2025 * | 1.09B 1.49B | EV / Sales 2024 * | 1.48 x |
Net Debt 2024 * | 3.55B 4.85B | Net Debt 2025 * | 3.35B 4.58B | EV / Sales 2025 * | 1.41 x |
P/E ratio 2024 * |
19.8
x | P/E ratio 2025 * |
18.6
x | Employees | - |
Yield 2024 * |
1.03% | Yield 2025 * |
1.1% | Free-Float | 98.93% |
Latest transcript on Leidos Holdings Inc
Managers | Title | Age | Since |
---|---|---|---|
Thomas Bell
CEO | Chief Executive Officer | 63 | 23-04-27 |
Christopher Cage
DFI | Director of Finance/CFO | 52 | 98-12-31 |
Michele Brown
CMP | Compliance Officer | - | 07-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harry Kraemer
BRD | Director/Board Member | 69 | 97-03-31 |
Bob Shapard
CHM | Chairman | 68 | 13-09-26 |
Surya Mohapatra
BRD | Director/Board Member | 74 | 16-08-15 |
1st Jan change | Capi. | |
---|---|---|
-14.23% | 189B | |
+1.41% | 168B | |
+4.49% | 157B | |
+6.84% | 102B | |
+37.66% | 85.01B | |
+13.18% | 83.75B | |
-4.64% | 73.04B | |
-21.53% | 52.32B | |
-7.69% | 43.86B |